Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  CVD Clinical 1. Subject is ≥18 years old 2. Eligible for percutaneous endovascular intervention 3. Documented severe (70%) symptomatic intracranial stenosis 4. Acceptable candidate for intracranial stenting 5. Subject (or legal guardian) understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed 6. Subject willing to comply with all specified follow-up evaluations Angiographic 1. Target lesion located in intracranial internal artery, intracranial vertebral artery, basilar artery or middle cerebral artery 2. Target lesion must be symptomatic 3. Target lesion diameter stenosis ≥70% 4. Reference vessel diameter (RVD): ≥2.0 mm to ≤6.0 mm 5. Cumulative target lesion length (area to be treated must be completely coverable by one study stent) ≤30 mm 6. Target lesion is presumed accessible by endovascular treatment. 7. One non target lesion may be treated in a non target vessel 8. Non-target lesion in non-target vessel must be treated with a commercially available stent. 9. Treatment of a non target lesion (if performed) must be deemed a clinical angiographic success, without requiring use of unplanned additional stent(s). 10. Treatment must be completed prior to treatment of target lesion  Contraindication to ASA, or to both clopidogrel and ticlopidine Known hypersensitivity to atorvastatin Known allergy to stainless steel Known allergy to platinum Previous treatment of the target vessel with angioplasty Previous treatment of the target vessel with stent Previous treatment of any non target vessel with stent within 9 months of the index procedure Planned endovascular treatment to post index procedure Planned or actual target vessel treatment with an unapproved device, directional or rotational intracranial atherectomy, laser, cutting balloon or transluminal extraction catheter immediately prior to stent placement Cerebral infarction within 1 month prior to the index procedure